Wockhardt Q1 FY27 results: Revenue up 36%, PAT up 55% YoY

Revenue Growth 20pctPat Growth 25pctExceptional ItemResults View source PDF Explain this filing

WOCKPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-3.1%Reaction day

₹1963.00

prior close

₹1970.00

announcement price

After-mkt

timing

Nifty Smallcap 250market+0.2%-3.3% vs market

Pharmaceuticals peers, median of 164sector+0.1%-3.2% vs sector

On the reaction day the stock moved 3.3 pts less than Nifty Smallcap 250 and 3.2 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.4

10m

-0.7

15m

-1.4

30m

-0.8

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-3.1+0.2-3.3+0.1-3.2

Next day

-6.2-0.1-6.1-0.4-5.7

-2.7+0.1-2.8+0.1-2.8

-1.6-0.4-1.2-0.4-1.1

-3.7-0.2-3.5-0.9-2.8

-5.3+0.0-5.3-0.5-4.8

-6.8-0.0-6.7-1.0-5.8

15d

-5.8+0.1-5.9-0.6-5.2

+10.8-0.0+10.8+0.9+9.9

+0.1-3.1+3.2-3.1+3.2

—————

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 164Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Wockhardt reported Q1FY27 standalone revenue of Rs 561 Cr, up 35.8% YoY from Rs 413 Cr. Net profit rose about 55% YoY to Rs 107 Cr from Rs 69 Cr. EPS stood at Rs 6.62 vs Rs 4.25. Consolidated revenue grew 25.9% to Rs 929 Cr with net profit of Rs 107 Cr versus a loss of Rs 108 Cr in Q1FY26. Auditor MSKC and Associates issued a clean limited review report.

Likely market impact

Strong YoY growth in both revenue and profits on standalone and consolidated bases; positive earnings momentum for shareholders.